Induction chemoimmunotherapy and surgery for unresectable stage III non-small cell lung cancer.

ABSTRACT:

Background

Concurrent chemoradiation plus consolidation immunotherapy is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), however, whether induction chemoimmunotherapy plus surgery can provide good efficiency and safety for this population is unclear. This study aims to evaluate the efficacy and safety of induction chemoimmunotherapy plus surgery in unresectable stage III NSCLC.

Methods

Patients with stage I-III NSCLC receiving neoadjuvant/induction chemoimmunotherapy were screened. Kaplan-Meier method, propensity score matching (PSM), Cox regression, and subgroup and sensitivity analysis were used for comparation in disease-free survival (DFS) and overall survival (OS). Perioperative safety was also analyzed.

Results

A total of 425

SUBMITTER: Wang S 

PROVIDER: S-EPMC12541860 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature